Core Laboratories Nv Stock Earnings Reports

Core Laboratories reported a Q1 2026 quarter marked by significant near-term headwinds tied to the Middle East conflict, ongoing Russia/Ukraine disruptions, and severe weather in North America and the Mediterranean. These events caused project delays, temporary facility closures, disrupted assay and completion field work, and damaged one facility, resulting in a sequential revenue decline and compressed margins. Consolidated revenue was $121.8 million (down 12% sequentially, down 1% YoY). Reservoir Description revenue was $82.0 million (down 11% sequentially) with ex-items operating margin of ~6%; Production Enhancement revenue was $40.0 million (down ~13% sequentially) with ex-items operating margin of ~5%. Q1 net income ex-items was $2.7 million (GAAP loss of $0.8M); EPS ex-items $0.06. Operating cash flow was $4M and free cash flow $0.5M; net debt $94.2M and leverage ~1.2x. Management reiterated its three financial tenets: maximize free cash flow, maximize return on invested capital, and return excess cash to shareholders (continued dividend and opportunistic buybacks—51k shares repurchased in Q1). Guidance for Q2 2026: consolidated revenue $123M–$131M, operating income $6.4M–$10.2M (approx. 7% margins), EPS $0.06–$0.12. Strategic positives include continued technology deployment (RAPID digital reservoir data platform, diagnostic wins such as FLOWPROFILER and GTX solutions) and a constructive multi-year view of demand driven by persistent global production decline rates and the need for new developments—particularly international offshore and non-U.S. conventional projects. Capital discipline remains a priority with 2026 capex (ex rebuild) expected $15M–$18M.